Sianature



Please type a plus sign (+) inside this box

BOX 401, 40 KING STREET WEST, TORONTO, CANADA PHONE (416) 364-7311 • FAX (416) 361-1398 • WWW.BERESKINPARR.COM

PTO/SB/05 (11-00) Approved for use through 10/31/2002. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE VA

April 9, 2001

Date

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 11014-24/MG UTILITY Attorney Docket No. ARTUR PEDYCZAK PATENT APPLICATION First Inventor TRANSMITTAL IMMUNOGENIC PEPTIDES DRIVED FROM ... Title Express Mail Label No. (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission 2. See 37 CFR 1.27. (if applicable, all necessary) Specification 40 [Total Pages a. Computer Readable Form (CRF) (preferred arrangement set forth below) - Descriptive title of the invention Specification Sequence Listing on: Cross Reference to Related Applications CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, ii. 🗹 or a computer program listing appendix Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention **ACCOMPANYING APPLICATION PARTS** Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) 9. - Claim(s) 37 CFR 3.73(b) Statement Power of - Abstract of the Disclosure 10. (when there is an assignee) Attorney English Translation Document (if applicable) 4. Drawing(s) (35 U.S.C. 113) [Total Sheets Copies of IDS Information Disclosure 5. Oath or Declaration [Total Pages Citations Statement (IDS)/PTO-1449 Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuationIdivisional with Box 18 completed) 13. Preliminary Amendment a. Return Receipt Postcard (MPEP 503) 14. 🗸 b. (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) DELETION OF INVENTOR(S) 15 Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR Request and Certification under 35 U.S.C. 122 16. 1.63(d)(2) and 1.33(b). (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 6. V Application Data Sheet. See 37 CFR 1.76 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No.:_ Prior englication information: Examine Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. DRESS **7** Customer Number or Bar Code Label Name Bereskin & Parr PATENT TRADEMARK OFFICE Box 401 40 King Street West Address Toronto State Ontario Zip Code M5H 3Y2 City Canada (416) 364-7311 (416) 361-1398 Country Fax Telephone **ANITA NADOR** 47,366 Name (Print/Type) Registration No. (Attorney/Agent)

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

BERESKIN & PARR

UNITED STATES APPLICATION

Title:

IMMUNOGENIC PEPTIDES DERIVED FROM PROSTATE-

SPECIFIC ANTIGEN (PSA) AND USES THEREOF

Inventors:

Artur Pedyczak, Pele Chong, Charles D Y Sia



Barristers and Solicitors/Patent and Trade Mark Agents Practice Restricted to Intellectual Property Law

April 9, 2001

Anita Nador B.A. (Molec. Biophys./Biochem), LL.B. 416 957 1684 anador@bereskinparr.com

Our Reference:

11014-24

The Commissioner of Patents and Trademarks Washington, D.C. U.S.A. 20231

Dear Sir:

Re:

U.S. Regular Patent Application

Claiming Priority from U.S. Provisional Patent Application No. 60/195,456

Entitled:

Immunogenic Peptides Derived From Prostate-

Specific Antigen (PSA) and Uses Thereof

Inventors: Artur Pedyczak, Pele Chong, Charles D.Y. Sia

Applicants are submitting the above-identified patent application for filing at the United States Patent and Trademark Office.

Applicants are submitting herewith (1) a Sequence Listing in paper form; (2) a Sequence Listing in computer readable form (a 3.5" floppy diskette) in the ASCII format and (3) a statement (set forth below) that the paper form and the computer readable form of the Sequence Listing are the same.

In accordance with the requirements of 37 C.F.R. 1.821-1.825 the undersigned verifies that the paper form of the Sequence Listing and the computer readable form of the Sequence Listing are the same.

Respectfully submitted

ARTHUR PEDYCZAK, PELE CHONG CHARLES D.Y. SIA

Anita Nador

Registration No. 47,366

BERESKIN & PARR

(Agents for the Applicants)

Enclosure